Electra Therapeutics IPO
Electra Therapeutics is a biotechnology company focused on developing innovative therapies for neurological and psychiatric disorders. The company's pipeline targets conditions with significant unmet medical needs, making it a potential area of interest for biotech investors seeking exposure to CNS therapeutics.
Key Facts
| Industry | Biotechnology |
| Funding | Raised $325-$347 million through IPO at $14-$16 per share (priced above midpoint); achieved approximately $977.6 million valuation; now trading publicly on Nasdaq under ticker ETRA |
About Electra Therapeutics
Electra Therapeutics is a biotechnology company developing novel therapeutics targeting neurological and psychiatric disorders. The company focuses on addressing conditions where current treatment options are limited or inadequate, representing a significant market opportunity in the CNS therapeutics space.
The biotechnology sector has seen strong investor interest in companies with differentiated approaches to treating brain disorders, particularly given the high unmet medical need and large patient populations. Electra Therapeutics' development programs aim to leverage innovative mechanisms of action to provide better outcomes for patients suffering from debilitating neurological and psychiatric conditions.
As with many private biotech companies, Electra Therapeutics' path to public markets will likely depend on the strength of its clinical data, the competitive landscape, and overall market conditions for life sciences IPOs.
IPO Status
Electra Therapeutics has successfully completed its initial public offering and began trading on September 18, 2026. The company had filed for an IPO with the SEC, setting terms to raise between $325 million and $347 million with a price range of $14-$16 per share, targeting a valuation of approximately $977.6 million. Multiple sources reported that the IPO was expected to price above the midpoint of its range, indicating strong investor demand. The company now trades on Nasdaq under the ticker symbol ETRA, with legal counsel provided by Cooley and Latham & Watkins. As an antibody-focused biotechnology company targeting inflammatory diseases, Electra is using the IPO proceeds to fund its drug candidate through Phase 3 clinical trials. The successful public offering reflects strong market appetite for biotech IPOs and investor confidence in the company's precision immune therapy approach. Led by a former Gilead executive, Electra has entered the public markets with a clear clinical development pathway and significant capital to advance its pipeline.
Competitors
Frequently Asked Questions
Does Electra Therapeutics have a stock?
No, Electra Therapeutics has not had an IPO yet. The company remains privately held, though it is expected to potentially pursue public markets in the future. Sign up for alerts to stay informed.
When is the Electra Therapeutics IPO date?
No official IPO date has been announced for Electra Therapeutics. The company has not yet filed registration documents with the SEC, so the timeline remains uncertain. Sign up for alerts to stay informed.
How can I buy Electra Therapeutics stock?
Electra Therapeutics stock is not currently available for purchase as the company is privately held. Once the company files for and completes an IPO, shares would become available through brokerage accounts on public exchanges. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts